Novo Nordisk


Company information coming soon

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes, obesity and other serious chronic diseases.

We aim to be the leading force in the science behind obesity, and we do so by pioneering scientific breakthroughs, expanding access to our medicines and working with scientific and medical experts to increase awareness of obesity as a serious and chronic disease.

Nearly 100 years of expertise in treating diabetes has given Novo Nordisk the knowledge to pursue innovative approaches to fighting obesity. We aim to be the leading force in the science behind obesity, and we do so by pioneering scientific breakthroughs, expanding access to our medicines and working with scientific and medical experts to increase awareness of obesity as a serious and chronic disease.

Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries.

Thank you for our sponsors who have supported the Association for the Study of Obesity (ASO) towards covering the costs of UKCO 2024. All sponsors have had no influence over the creation, development or content of the programme, apart from the Industry Led Symposium.

The UK Congress on Obesity has been instigated and organised by ASO. Sponsors have contributed funding towards this event in return for exhibition space. They have had no input into the agenda or the selection of speakers with the exception of any sponsored symposia which are clearly indicated. View a full list of sponsors.